WaveMan
WaveMan · Company
PCRX · Pacira Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PCRX Pacira BioSciences (PCRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001396814
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
127
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $194.1K priced

What the filings say about PCRX

Insiders, 180 days
-$660.7K net sold
3 sellers · 25% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$288.5K
2 notices

Pacira BioSciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Pacira BioSciences, Inc. insiders sold a net $660.7K of stock across 142 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
RIKER LAUREN
Senior Vice President, Finance
SELL
2026-10-09 SECtraded 2026-10-08
6,000
$217.9K
+0.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 11, 2026.
  • The trade is 9.6% of the 62,284 shares held after it.
  • No other insider sold within 30 days.
  • 127 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior Vice President, Finance RIKER LAUREN sold about $217.9K of PCRX under a 10b5-1 plan on Oct 8, 2026; 127 funds added in the latest 13F quarter.
SLONIN JONATHAN
Chief Medical Officer
SELL
2026-08-18 SECtraded 2026-08-17
3,040
$70.6K
+49.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Mar 17, 2026.
  • The trade is 1.4% of the 216,383 shares held after it.
  • No other insider sold within 30 days.
  • 127 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer SLONIN JONATHAN sold about $70.6K of PCRX on Aug 17, 2026; 127 funds added in the latest 13F quarter.
RIKER LAUREN
Senior Vice President, Finance
SELL
2026-06-12 SECtraded 2026-06-11
6,115
$143.7K
+60.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 2, 2026.
  • The trade is 9.8% of the 62,284 shares held after it.
  • 1 other insider sold within 30 days.
  • 127 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior Vice President, Finance RIKER LAUREN sold about $143.7K of PCRX on Jun 11, 2026; 1 other insider sold within 30 days and 127 funds added in the latest 13F quarter.
WILLIAMS KRISTEN
Chief Administrative Officer
SELL
2026-06-05 SECtraded 2026-06-04
10,259
$228.5K
+59.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 2, 2026.
  • The trade is 6.1% of the 167,062 shares held after it.
  • 1 other insider sold within 30 days.
  • 127 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer WILLIAMS KRISTEN sold about $228.5K of PCRX on Jun 4, 2026; 1 other insider sold within 30 days and 127 funds added in the latest 13F quarter.
Cross Shawn
Chief Financial Officer
SELL
2026-04-24 SECtraded 2026-04-23
12,941
$325.6K
+42.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Apr 22, 2026.
  • The trade is 12.3% of the 105,341 shares held after it.
  • No other insider sold within 30 days.
  • 127 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Cross Shawn sold about $325.6K of PCRX on Apr 23, 2026; 127 funds added in the latest 13F quarter.
142 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 137 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$660.7K over 180 days
-$288.5K over 90 days
below 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
127 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
+3.6% year over year
more than 50% of Pharma & Biotech
Margin
1.0% net margin
more than 74% of Pharma & Biotech
Buybacks
$50.0M repurchased, FY to 2026-06-30
more than 56% of Pharma & Biotech
Short interest
20.6% of the float short (float per yahoo 2026-10-26) · 15.1 days to cover · settled 2026-09-30
more than 94% of Pharma & Biotech
What changed in the last 30 days
Oct 9Senior Vice President, Finance RIKER LAUREN sold $217.9K under a 10b5-1 plan (Oct 8)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 8Officer RIKER LAUREN filed to sell $217.9K by Oct 8 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch PCRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.0%12M
-12%+15%+42%+68%2025-102025-122026-022026-042026-062026-082026-10 2025-12-09 · Cross Shawn sold $397.9K2026-04-23 · Cross Shawn sold $325.6K2026-02-02 · WILLIAMS KRISTEN sold $269.7K2025-11-10 · Cross Shawn sold $266.4K2025-12-10 · Cross Shawn sold $228.9K2026-06-04 · WILLIAMS KRISTEN sold $228.5K2026-10-08 · RIKER LAUREN sold $217.9K2026-04-20 · Cross Shawn sold $193.9K2026-06-11 · RIKER LAUREN sold $143.7K2025-11-17 · SLONIN JONATHAN sold $95.4K2026-02-02 · RIKER LAUREN sold $83.2K2026-03-17 · SLONIN JONATHAN sold $74.4K2026-04-21 · Cross Shawn sold $71.2K2026-08-17 · SLONIN JONATHAN sold $70.6K2026-04-22 · Cross Shawn sold $37.5K2026-01-05 · RIKER LAUREN sold $34.3K2026-03-17 · Froimson Mark sold $10.9K2026-10-08 · RIKER LAUREN filed to sell $217.9K2026-08-17 · SLONIN JONATHAN filed to sell $70.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PCRX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
6,705,809 sh
$170.1M
Doma Perpetual Capital Management LLC
2,777,794 sh
$70.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
2,406,238 sh
$61.0M
DIMENSIONAL FUND ADVISORS LP
2,103,245 sh
$53.4M
STATE STREET CORP
2,059,977 sh
$52.3M

Congress trades in PCRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PCRX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
RIKER LAUREN
Filed 2026-10-08
$217.9K
SLONIN JONATHAN
Filed 2026-08-17
$70.6K

PCRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Easterly Snow Long/Short Opportunity Fund
$3.2M position · as of 2026-05-31
2.9%
ABSOLUTE FLEXIBLE FUND
$999.1K position · as of 2026-06-30
2.4%
Impax Small Cap Fund
$19.0M position · as of 2026-06-30
2.0%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.1M position · as of 2026-06-30
1.7%
PROFUND VP PHARMACEUTICALS
$184.6K position · as of 2026-06-30
1.6%
M3Sixty Small Cap Growth Fund
$145.2K position · as of 2026-05-31
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · David Stack
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$6.9M
$4.2M
$1.5M
-26%
-9%
2022
$6.9M
$887.1K
$2.0M
-15%
-10%
2021
$6.9M
$5.5M
$2.1M
+33%
+40%
2020
$9.3M
$13.6M
$2.4M
+32%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $660.7K sold by insiders over 180 days, 127 funds added last quarter, $288.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PCRX financials

Revenue growth
+3.6%
XBRL, annual
Net margin
1.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$746.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+2.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$179.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.54x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
0.52x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Return on equity
+2.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+1.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+2.0%
operating income after a 17.1% effective tax rate, over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+1.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
103.94x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$1.6B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
+12.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$726.4M$701.0M$675.0M$666.8M
Operating income$19.2M-$73.4M$87.7M$60.0M
Net income$7.0M-$99.6M$42.0M$15.9M
EPS (diluted)0.16-2.150.890.34
Operating cash flow$152.0M$189.4M$154.6M$145.3M
Cash$158.5M$276.8M$153.3M$104.1M
Long-term debt$372.2M$383.5M$522.4M$689.5M
Buybacks$148.3M$25.0M$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

PCRX Stock Sonar score 6/7 axes

Find similar shapesCompare

PCRX ranks highest on institutional and government (78th percentile) and profitability (64th), and lowest on insider conviction (21st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
64
Inputs
  • Return on equity+2.0% · 82 pct, sector of 545
  • Return on assets+1.1% · 82 pct, sector of 691
  • Return on invested capital+2.0% · 7 pct, sector of 45
  • Return on capital employed+1.7% · 86 pct, sector of 576
Financial health
59
Inputs
  • Debt to equity0.54x · 30 pct, sector of 352
  • Cash flow to debt0.52x · 89 pct, sector of 371
Growth
50
Inputs
  • Revenue growth, YoY+3.6% · 50 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
21
Inputs
  • Net Form 4 buying (codes P and S), 180d-$443K · 42 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
78
Inputs
  • Funds adding, latest quarter127 · 78 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
23
Inputs
  • Short interest, % of float+20.6% · 14 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.5% · 31 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PCRX filings, in plain words

Are Pacira BioSciences insiders buying or selling PCRX?

In the 180 days to 2026-10-28, Pacira BioSciences insiders were net sellers, a net $660.7K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of PCRX?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $288.5K of stock; the latest, by RIKER LAUREN, was filed 2026-10-08.

Read the full summary

In the 180 days to 2026-10-28, Pacira BioSciences insiders were net sellers of PCRX, a net $660.7K across purchases and sales reported on Form 4 by 3 sellers. 25% of the 4 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $288.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies